| abstract |
Disintegrin variants and pharmaceutical uses thereof are disclosed. Disintegrin variants are isolated polypeptides having integrin avβ3 receptor antagonistic activity and having substantially lower integrin aIIbβ3 and / or a5β1 receptor blocking activity than wild-type disintegrins. Contains peptides. A disintegrin variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence and produces a polypeptide having substantially lower affinity for integrin aIIbβ3 and / or a5β1 than wild-type disintegrin. Disintegrin variants include avβ3 integrin in mammals including osteoporosis, bone tumor or cancer growth, tumor growth and metastasis associated with angiogenesis, tumor metastasis in bone, rheumatoid arthritis, and osteoarthritis. Useful for the treatment and / or prevention of related diseases. [Selection figure] None |